Role of swa1nson1ne in hematopoffitic recovery
A number of lymphokines and growth factors are involved in the proliferation/differentiation processes of bone marrow (BM) hematopoietic progenitor cells. The ability of swainsonine (SW), an indolizine alkaloid immunomodulator, to stimulate the proliferation /differentiation of BM hematopoietic stem cells was tested in nontumprbearing CS7BL/6 female mice during and following 3 consecutive treatment-cycles with LDW methotrexate (MTX, 410 mg/kg, ip). The effects of swainsonine treatment on the hématologie parameters, cellularity and colony forming activities (CPUs of granulocytemacrophage, pluripotent mixed colonies and erythroid blast) of BM and spleen stem cells were studied and correlated with survival of mice. SW treatment significantly accelerated recovery from neutropenia and severe hematopoietic injury by facilitating restoration of BM cellularity and competence. Also SW significantly stimulated CPUs of spleen and BM cells. These effects positively correlated with the significant reduction in lethality due to courses of MTX treatment. These findings demonstrate that SW is a novel immunomodulatory agent with potential usefulness in the amelioration of severe myelosuppression associated with high-dose intensive chemotherapy and autologous BM transplantation.
Oredipe, O. A., "Role of swa1nson1ne in hematopoffitic recovery" (1996). Howard University Cancer Center Faculty Publications. 189.